GRANT Tuesday, September 30, 2014- 11:45 BrightFocus Foundation Variable October 14, 2014 BrightFocus Foundation Alzheimer's Disease Research Award ...
THERAPEUTICS AstraZeneca Immunotherapy (passive) Amyloid-Related In February 2014, AstraZeneca started a multicenter phase 1 trial in the U.S., which is to enroll 242 people with mild to moderate Alzheimer's disease. The study will evaluate single and multiple ...
THERAPEUTICS Eli Lilly & Co. N3pG-amyloid-beta Monoclonal Antibody Immunotherapy (passive) Amyloid-Related In May 2013, Lilly started a phase 1 study in 100 people on the spectrum of mild cognitive impairment due to Alzheimer's disease to mild Alzheimer' ...
PAPER Orta-Salazar E, Aguilar-Vázquez A, Martínez-Coria H, Luquín-De Anda S, Rivera-Cervantes M, Beas-Zarate C, Feria-Velasco A, Díaz-Cintra S
REST/NRSF-induced changes of ChAT protein expression in the neocortex and hippocampus of the 3xTg-AD mouse model for Alzheimer's disease.Life Sci. 2014 Sep 24; PubMed: 25261598
PAPER Roses AD, Lutz MW, Saunders AM, Goldgaber D, Saul R, Sundseth SS, Akkari PA, Roses SM, Gottschalk WK, Whitfield KE, Vostrov AA, Hauser MA, Allingham RR, Burns DK, Chiba-Falek O, Welsh-Bohmer KA25260913
PAPER Ahmed RM, Paterson RW, Warren JD, Zetterberg H, O'Brien JT, Fox NC, Halliday GM, Schott JM25261571
No filters selected